Slobod, Karen S., Coleclough, Chris, Bonsignori, Mattia, Brown, Scott A., Zhan, Xiaoyan, Surman, Sherri, Zirkel, Amy, Jones, Bart G., Sealy, Robert E., Stambas, John, Brown, Brita, Lockey, Timothy D., Freiden, Pamela J., Doherty, Peter C., Blanchard, James L., Martin, Louis N. and Hurwitz, Julia L. 2005, HIV vaccine rationale, design and testing, Current HIV research, vol. 3, no. 2, pp. 107-112, doi: 10.2174/1570162053506928.
A central obstacle to the design of a global HIV vaccine is viral diversity. Antigenic differences in envelope proteins result in distinct HIV serotypes, operationally defined such that antibodies raised against envelope molecules from one serotype will not bind envelope molecules from a different serotype. The existence of serotypes has presented a similar challenge to vaccine development against other pathogens. In such cases, antigenic diversity has been addressed by vaccine design. For example, the poliovirus vaccine includes three serotypes of poliovirus, and Pneumovax® presents a cocktail of 23 pneumococcal variants to the immune system. It is likely that a successful vaccine for HIV must also comprise a cocktail of antigens. Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific Bcell and T-cell responses, are reviewed.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact email@example.com.